Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2671 to 2685 of 9008 results

  1. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MT604) (MIB268)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  2. Bepirovirsen for treating chronic hepatitis B [ID6608]

    In development Reference number: GID-TA11803 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]

    In development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development Reference number: GID-TA11422 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  5. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  11 September 2026

    NICE guideline
    In development

  6. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]

    In development Reference number: GID-TA11869 Expected publication date:  24 March 2027

    Technology appraisal guidance
    In development

  8. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 21 May 2026.

    Technology appraisal guidance
    In consultation

  9. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 29 April 2026.

    Technology appraisal guidance
    In consultation

  10. Prostate cancer: diagnosis and management (update): scoping

    We are listening to your views on this NICE guideline. Comments close 27 May 2026.

    NICE guideline
    In consultation

  11. Sleep disordered breathing

    Awaiting development Reference number: GID-QS10096 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

    In development Reference number: GID-TA11576 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  15. Cancer case finding technologies to support early recognition of suspected cancer symptoms in primary care: early use assessment

    In development Reference number: GID-HTG10176 Expected publication date: TBC

    HealthTech guidance
    In development